My Cart

BDNF

BDNF Overview

English NameBrain-derived neurotrophic factorApproved Drugs1
Drugs in Clinical Trials8Target SynonymBrain-Derived Neurotrophic Factor,Abrineurin,ANON2,Brain Derived Neurotrophic Factor,BULN2,ProBDNF,Neurotrophin
Highest Development StagePhase 3 Clinical
English NameBrain-derived neurotrophic factor
Target SynonymBrain-Derived Neurotrophic Factor,Abrineurin,ANON2,Brain Derived Neurotrophic Factor,BULN2,ProBDNF,Neurotrophin
Approved Drugs1
Drugs in Clinical Trials8
Highest Development StagePhase 3 Clinical

BDNF Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (4)

  • Tag

    Tag Free (4)

  • Conjugate

    Unconjugated (4)

BDNF Background

Brain-derived neurotrophic factor (BDNF) along with nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the neurotrophin family of trophic factors. The neurotrophins play essential roles in the development, survival, and function of a wide range of neurons in both the peripheral and central nervous systems. The neurotrophins interact with two cell surface receptors, the low affinity P75 receptor and the Trk family of high affinity tyrosine kinase receptors. NGF preferentially binds TrkA, BDNF and NT4/5 bind TrkB, and NT-3 binds TrkC (and TrkA to a lesser extent).

BDNF Synonyms

BDNF,ANON2,BULN2,Abrineurin

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Tetramethylpyrazine NitronePhase 3 ClinicalJinan UniversityDiabetes Mellitus, Type 2; Stroke; Diabetic Nephropathies; Amyotrophic Lateral Sclerosis
Details
ACT-01ACT-01; OCS-05; BN-201; G-79Phase 2 ClinicalPromius PharmaKeratosis, Actinic; Optic Neuritis; Demyelinating Diseases
Details
MP-101MP101; MP-101Phase 2 ClinicalMitochon PharmaceuticalsMultiple Sclerosis; Huntington Disease; Amyotrophic Lateral Sclerosis
Details
ALTO-100ALTO-100Phase 2 ClinicalAlto Neuroscience IncDepressive Disorder, Major; Bipolar I Disorder; Stress Disorders, Post-Traumatic; Bipolar II Disorder
Details
AC-102AC-102Phase 2 ClinicalAudioCure Pharma GmbHTinnitus; Hearing Loss, Sensorineural; Hearing Loss, Sudden
Details
TTI-0102TTI-0102Phase 2 ClinicalVa Office Of Research And DevelopmentRett Syndrome; Leigh Disease; Metabolic Dysfunction-Associated Steatotic Liver Disease; MELAS Syndrome; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Stress Disorders, Post-Traumatic
Details
JS1-1-01JS1-1-01Phase 2 ClinicalTianjin Tasly Pharmaceutical Co LtdDepression; Depressive Disorder, Major; Depressive Disorder
Details
AAV2-BDNF gene therapy (University Of California San Diego)Phase 1 ClinicalUniversity Of California San DiegoAlzheimer Disease; Cognitive Dysfunction
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Laquinimod SodiumTV-5600; ABR-215062; SAIK-MSApprovedActive Biotech AbNerventraMultiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Huntington Disease; Arthritis; Uveitis; Eye Diseases; Crohn Disease
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland